Annual EBIT
-$28.71 M
-$681.00 K-2.43%
December 31, 2023
Summary
- As of February 26, 2025, TRVI annual earnings before interest & taxes is -$28.71 million, with the most recent change of -$681.00 thousand (-2.43%) on December 31, 2023.
- During the last 3 years, TRVI annual EBIT has risen by +$3.61 million (+11.18%).
- TRVI annual EBIT is now -200.78% below its all-time high of -$9.54 million, reached on December 31, 2017.
Performance
TRVI EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$13.27 M
-$913.00 K-7.39%
September 30, 2024
Summary
- As of February 26, 2025, TRVI quarterly earnings before interest & taxes is -$13.27 million, with the most recent change of -$913.00 thousand (-7.39%) on September 30, 2024.
- Over the past year, TRVI quarterly EBIT has dropped by -$5.47 million (-70.18%).
- TRVI quarterly EBIT is now -235.75% below its all-time high of -$3.95 million, reached on March 31, 2018.
Performance
TRVI Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$44.34 M
-$5.56 M-14.35%
September 30, 2024
Summary
- As of February 26, 2025, TRVI TTM earnings before interest & taxes is -$44.34 million, with the most recent change of -$5.56 million (-14.35%) on September 30, 2024.
- Over the past year, TRVI TTM EBIT has dropped by -$15.63 million (-54.46%).
- TRVI TTM EBIT is now -1021.65% below its all-time high of -$3.95 million, reached on March 31, 2018.
Performance
TRVI TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
TRVI EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2.4% | -70.2% | -54.5% |
| 3 y3 years | +11.2% | -91.0% | -31.4% |
| 5 y5 years | -40.1% | -80.1% | -69.6% |
TRVI EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -2.4% | +12.4% | -152.8% | at low | -69.5% | at low |
| 5 y | 5-year | -10.1% | +12.4% | -152.8% | at low | -69.6% | at low |
| alltime | all time | -200.8% | +12.4% | -235.8% | at low | -1021.6% | at low |
Trevi Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$13.27 M(+7.4%) | -$44.34 M(+14.3%) |
| Jun 2024 | - | -$12.36 M(+13.3%) | -$38.77 M(+16.0%) |
| Mar 2024 | - | -$10.91 M(+39.9%) | -$33.44 M(+16.5%) |
| Dec 2023 | -$28.71 M(+2.4%) | -$7.80 M(+1.2%) | -$28.71 M(+9.7%) |
| Sep 2023 | - | -$7.71 M(+9.8%) | -$26.16 M(-1.0%) |
| Jun 2023 | - | -$7.02 M(+13.7%) | -$26.43 M(-2.7%) |
| Mar 2023 | - | -$6.18 M(+17.6%) | -$27.17 M(-3.1%) |
| Dec 2022 | -$28.02 M(-14.5%) | -$5.25 M(-34.2%) | -$28.02 M(-9.6%) |
| Sep 2022 | - | -$7.98 M(+2.8%) | -$30.99 M(+3.4%) |
| Jun 2022 | - | -$7.76 M(+10.4%) | -$29.96 M(-5.5%) |
| Mar 2022 | - | -$7.03 M(-14.4%) | -$31.70 M(-3.2%) |
| Dec 2021 | -$32.76 M | -$8.22 M(+18.2%) | -$32.76 M(-2.9%) |
| Sep 2021 | - | -$6.95 M(-26.8%) | -$33.74 M(-0.9%) |
| Jun 2021 | - | -$9.50 M(+17.4%) | -$34.03 M(+6.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$8.09 M(-12.0%) | -$31.93 M(-1.2%) |
| Dec 2020 | -$32.32 M(+24.0%) | -$9.20 M(+27.0%) | -$32.32 M(+9.0%) |
| Sep 2020 | - | -$7.24 M(-2.1%) | -$29.66 M(-0.4%) |
| Jun 2020 | - | -$7.40 M(-12.8%) | -$29.79 M(-0.1%) |
| Mar 2020 | - | -$8.48 M(+29.7%) | -$29.81 M(+14.0%) |
| Dec 2019 | -$26.07 M(+27.2%) | -$6.54 M(-11.2%) | -$26.14 M(+2.0%) |
| Sep 2019 | - | -$7.37 M(-0.6%) | -$25.63 M(+7.1%) |
| Jun 2019 | - | -$7.42 M(+54.1%) | -$23.94 M(+12.1%) |
| Mar 2019 | - | -$4.81 M(-20.2%) | -$21.35 M(+4.2%) |
| Dec 2018 | -$20.50 M(+114.7%) | -$6.03 M(+6.2%) | -$20.50 M(+41.7%) |
| Sep 2018 | - | -$5.68 M(+17.5%) | -$14.46 M(+64.6%) |
| Jun 2018 | - | -$4.83 M(+22.2%) | -$8.79 M(+122.2%) |
| Mar 2018 | - | -$3.95 M | -$3.95 M |
| Dec 2017 | -$9.54 M | - | - |
FAQ
- What is Trevi Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Trevi Therapeutics?
- What is Trevi Therapeutics annual EBIT year-on-year change?
- What is Trevi Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Trevi Therapeutics?
- What is Trevi Therapeutics quarterly EBIT year-on-year change?
- What is Trevi Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Trevi Therapeutics?
- What is Trevi Therapeutics TTM EBIT year-on-year change?
What is Trevi Therapeutics annual earnings before interest & taxes?
The current annual EBIT of TRVI is -$28.71 M
What is the all time high annual EBIT for Trevi Therapeutics?
Trevi Therapeutics all-time high annual earnings before interest & taxes is -$9.54 M
What is Trevi Therapeutics annual EBIT year-on-year change?
Over the past year, TRVI annual earnings before interest & taxes has changed by -$681.00 K (-2.43%)
What is Trevi Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of TRVI is -$13.27 M
What is the all time high quarterly EBIT for Trevi Therapeutics?
Trevi Therapeutics all-time high quarterly earnings before interest & taxes is -$3.95 M
What is Trevi Therapeutics quarterly EBIT year-on-year change?
Over the past year, TRVI quarterly earnings before interest & taxes has changed by -$5.47 M (-70.18%)
What is Trevi Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of TRVI is -$44.34 M
What is the all time high TTM EBIT for Trevi Therapeutics?
Trevi Therapeutics all-time high TTM earnings before interest & taxes is -$3.95 M
What is Trevi Therapeutics TTM EBIT year-on-year change?
Over the past year, TRVI TTM earnings before interest & taxes has changed by -$15.63 M (-54.46%)